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Abstract. 
 
Mutations in the highly homologous prese-
nilin genes encoding presenilin-1 and presenilin-2 (PS1
and PS2) are linked to early-onset Alzheimer’s disease
(AD). However, apart from a role in early develop-
ment, neither the normal function of the presenilins
nor the mechanisms by which mutant proteins cause
AD are well understood. We describe here the proper-
ties of a novel human interactor of the presenilins
named ubiquilin. Yeast two-hybrid (Y2H) interaction,
 
glutathione 
 
S
 
-transferase pull-down experiments, and
colocalization of the proteins expressed in vivo, to-
gether with coimmunoprecipitation and cell fraction-
ation studies, provide compelling evidence that ubiqui-
lin interacts with both PS1 and PS2. Ubiquilin is
noteworthy since it contains multiple ubiquitin-related
domains typically thought to be involved in targeting
 
proteins for degradation. However, we show that ubiqui-
 
lin promotes presenilin protein accumulation. Pulse-
labeling experiments indicate that ubiquilin facilitates
increased presenilin synthesis without substantially
changing presenilin protein half-life. Immunohisto-
chemistry of human brain tissue with ubiquilin-speciﬁc
 
antibodies revealed prominent staining of neurons. More-
over, the anti-ubiquilin antibodies robustly stained
neuroﬁbrillary tangles and Lewy bodies in AD and
Parkinson’s disease affected brains, respectively. Our
results indicate that ubiquilin may be an important
modulator of presenilin protein accumulation and that
ubiquilin protein is associated with neuropathological
neuroﬁbrillary tangles and Lewy body inclusions in
diseased brain.
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Introduction
 
Alzheimer’s disease (AD)
 
1
 
 is a progressive neurodegener-
ative disorder characterized by impaired memory and cog-
nition, as well as altered behavior. The majority of AD
cases are late-onset, appearing in people over the age of
 
65. However, a small percent (
 
z
 
5%) of cases, termed
early-onset, arise at an unusually young age, as early as the
third decade of life. Molecular genetic analysis has linked
early-onset familial Alzheimer’s disease (FAD) to the au-
tosomal dominant inheritance of mutations in three genes:
 
the 
 
b
 
-amyloid precursor protein (APP) and two homolo-
gous genes, presenilin-1 and -2 (PS1 and PS2) (Hardy,
1997; Price et al., 1998). The mechanisms by which muta-
tions in these three genes cause AD are unresolved.
PS1 and PS2 are multitransmembrane proteins that
share 67% sequence identity. The topology of presenilins
is debatable, though the most widely drawn models show
proteins that weave through the membrane eight times,
with the NH
 
2
 
- and COOH-terminal domains and a large
“loop” between transmembrane domains six and seven all
oriented towards the cytoplasm (see Fig. 1 A) (Haass and
De Strooper, 1999). Although both proteins share exten-
sive sequence identity along their entire lengths, their
NH
 
2
 
-terminal domains and the second half of their loops
are highly divergent, suggesting that these unique regions
could modulate different functions of the two presenilins.
An examination of presenilin-linked FAD mutations
mapped so far reveals that most are missense mutations in
identical residues spread throughout the polypeptide in
both presenilins, suggesting that the conserved residues
are important for the function of the proteins.
Studies of presenilin homologues in various species have
indicated that presenilin genes are required for proper de-
 
velopment. Mutation of the 
 
Caenorhabditis elegans 
 
prese-
nilin gene, 
 
sel-12
 
, produces defects in vulva development
linked to cell signaling defects involving Notch-based re-
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b
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ceptors (Levitan and Greenwald, 1995; Haass and De
Strooper, 1999). Disruption of the 
 
Drosophila
 
 
 
melano-
gaster
 
 presenilin gene results in embryonic lethality, with
embryos displaying severe Notch-like phenotypes (Struhl
and Greenwald, 1999; Ye et al., 1999). Mammalian prese-
nilins also play important roles in early development, as
disruption of the mouse PS1 gene leads to death shortly af-
ter birth, with embryos displaying central nervous system
defects together with abnormal patterning of the axial
skeleton and spinal ganglia (Shen et al., 1997; Wong et al.,
1997). Interestingly, PS1
 
2
 
/
 
2
 
 mice can be rescued by a hu-
man transgenes containing FAD-linked mutations, indi-
cating that the FAD mutations do not affect presenilin
functions related to embryo development (Davis et al.,
1998; Qian et al., 1998). In contrast, disruption of the
mouse PS2 gene produces no obvious defects, but PS1/PS2
double knock-out mice die earlier at embryonic day 9.5
and, like PS1
 
2
 
/
 
2
 
 mice, display severe misexpression of pro-
teins involved in Notch signaling (Donoviel et al., 1999;
Herreman et al., 1999). These results indicate that there is
functional redundancy between PS1 and PS2; PS1 can
compensate for PS2, but PS2 cannot compensate for PS1,
at least during early mouse development.
Both human presenilin genes are ubiquitously ex-
pressed, but at low levels. In brain the proteins are more
highly expressed in neurons than glia (Price et al., 1998).
Knowledge of where presenilin proteins localize in cells is
important for understanding their function. However, un-
certainties exist regarding their precise subcellular local-
ization. In neurons, endogenous PS1 and PS2 have been
localized to the ER and to vesicular structures of the so-
matodentritic compartment and axons (Price et al., 1998;
Haass and De Strooper, 1999). When overexpressed, the
proteins predominantly localize to the ER, the Golgi com-
plex, and the nuclear envelope (Kovacs et al., 1996; Janicki
and Monteiro, 1997; Haass and De Strooper, 1999). How-
ever, in nonneuronal cells, endogenous presenilins have
been localized to the ER, Golgi complex, centrosomes,
centromeres, and cell surface (Georgakopoulos et al.,
1999; Haass and De Strooper, 1999; Raina et al., 1999). It
is not known to what extent these diverse locations reflect
true sites of presenilin function.
The presenilin proteins have been linked to several cellu-
lar functions. Interestingly, some of these cellular functions
are compromised or altered by the expression of PS genes
containing FAD mutations. The presenilin proteins have
been shown to play important roles in apoptosis, calcium
homeostasis, cell cycle regulation, regulation of misfolded
proteins in the ER, and cleavage of APP (Guo et al., 1997;
Janicki and Monteiro, 1997, 1999; Cotman, 1998; Mattson
et al., 1998; Haass and De Strooper, 1999; Katayama et al.,
1999; Leissring et al., 1999; Niwa et al., 1999). Further clues
regarding presenilin functions are emerging from a growing
list of proteins with which presenilin interacts. Previously,
we identified and characterized calmyrin, a newly discov-
ered calcium-binding protein, which preferentially interacts
with the PS2 loop and modulates presenilin-induced cell
death (Stabler et al., 1999). Here, we describe a novel hu-
man presenilin-interacting protein, which we have named
ubiquilin. We describe evidence that indicates ubiquilin
modulates presenilin protein levels and is associated with
neuropathological lesions such as NFTs and Lewy bodies in
AD and PD affected brains.
 
Materials and Methods
 
Ubiquilin cDNA and Protein Sequences
 
The GenBank/EMBL/DDBJ ubiquilin cDNA accession number is
AF176069, and the ubiquilin protein accession number is AAD49751 (see
updated NM_013438).
 
Yeast Two-Hybrid Experiments
 
The yeast two-hybrid (Y2H) procedure that utilizes the LexA/transactiva-
tion system was performed, as described previously (Stabler et al., 1999).
The PS2 COOH-terminal 39-amino acids (residues K410–I448) (see Fig.
1, A and B) were used as bait to screen a human fetal brain cDNA library.
Out of 
 
z
 
10
 
7
 
 primary yeast transformants, 
 
z
 
50 clones were selected for
further analysis based on growth in the absence of leucine and a substan-
tial blue color change when grown on 5-bromo-4-chloro-3-indolyl-
 
b
 
-
 
D
 
-
galactopyranoside (X-gal) plates. False positives were subsequently elimi-
nated based on their interactions with negative-control baits, such as
LexA alone, nuclear lamin B, and CENP-C centromere protein. Plasmid
DNAs were isolated from clones that fulfilled the above requirements,
and the DNA sequences of their inserts were determined and compared
with the GenBank/EMBL/DDBJ databases using the BLAST search pro-
gram. Two of the interactors contained overlapping portions of the 3
 
9
 
 end
of a novel human transcript, which we named ubiquilin. Interaction of
ubiquilin proteins with various PS1 and PS2 baits were quantified in liquid
culture assays by the enzymatic conversion of 
 
o
 
-nitrophenyl-
 
b
 
-
 
D
 
-galacto-
pyranoside (ONPG) to 
 
o
 
-nitrophenol and 
 
D
 
-galactose by 
 
b
 
-galactosidase
enzyme encoded by a Y2H reporter plasmid.
 
Rapid Amplification of cDNA Ends (RACE)
 
5
 
9
 
 RACE, using strategically designed ubiquilin-specific primers, was per-
formed to obtain the full-length coding sequence of ubiquilin. The PCR
reactions were carried out according to the instructions provided by the
manufacturer, using an AP1 adaptor–ligated human adult brain cDNA li-
brary as template and the Advantage cDNA Polymerase Mix (CLON-
TECH Laboratories, Inc.). The procedure resulted in the isolation of
1,053 additional bps of the 5
 
9
 
 sequence, with respect to the longest original
Y2H clone. The full-length ubiquilin open reading frame (ORF) was sub-
sequently obtained by sequencing a human expressed sequence tag (EST)
clone (American Type Culture Collection), which provided an extra 108
bps of 5
 
9
 
 sequence, including the ATG start codon, a Kozak consensus se-
quence, and an upstream in-frame stop codon. In addition, comparison of
the sequence with the TIGR Tentative Human Consensus database re-
turned another independent EST sequence (THC296552), which corrobo-
rated the ATG start codon.
 
Radiation Hybrid Mapping
 
A GeneBridge 4 radiation hybrid panel (Research Genetics) was per-
formed with two ubiquilin gene-specific primers, RH1 (5
 
9
 
-GCAGCGA-
CAACTTTTGTCTAACCCTG-3
 
9
 
) and RH2 (5
 
9
 
-CAGGCACCA-
AATTTGGCGCAGTAG-3
 
9
 
), and each of the 93 indexed human
genomic DNA template pools. The conditions for the PCR reactions were
similar to that of the 5
 
9
 
 RACE procedure, except that a longer initial de-
naturation step was used. Positive and negative reactions (1 or 0, respec-
tively; 2 represents an ambiguous reaction) were compiled (0100010001
1002100110 0000011000 1011000000 1100000001 0010001001 0100010000
0111100000 1000000000 000), and the vector data was submitted to the
Whitehead Institute/MIT Center for Genome Research website (http://
carbon.wi.mit.edu:8000/cgi-bin/contig/rhmapper.pl) for comparison with
their radiation hybrid database.
 
Northern Blot Analysis
 
cDNA hybridization probes were 
 
32
 
P-radiolabeled by random primer la-
beling of 
 
z
 
100 ng of two ubiquilin cDNA restriction fragments, X (bases
1,132–1,860) and Y (bases 284–967), shown in Fig. 2 II. Each probe was
hybridized to a different human mRNA Northern blot, Human Multiple
Tissue Northern Blot I, and Human Brain MTN II, respectively (CLON-
TECH Laboratories, Inc.). After hybridization, the blots were washed
twice with 2.0
 
3
 
 SSC and 0.05% SDS at 50
 
8
 
C and then twice again with
0.1
 
3
 
 SSC and 0.1% SDS at 50
 
8
 
C, before exposure to autoradiography
film. Both blots were subsequently stripped in near-boiling temperature
0.5% SDS and then reprobed with radiolabeled human 
 
b
 
-actin cDNA
control probe (CLONTECH Laboratories, Inc.). The band intensities 
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were quantified using GelExpert 97 2.0 (Nucleotech Corp.), divided by
the 
 
b
 
-actin control band intensity from the same lane, and then normal-
ized against the lowest value.
 
Bacterial Expression of Ubiquilin Proteins
 
To express full-length nonfusion ubiquilin protein in bacteria, an NcoI/
XhoI cDNA fragment containing the entire ubiquilin ORF was subcloned
into pET-15b (Novagen) and then transformed into 
 
Escherichia coli
 
BL21(DE3). Ubiquilin protein expression was induced with 1.0 mM IPTG
at 37
 
8
 
C for 2–3 h. Bacteria were lysed, and the protein extracts were sepa-
rated by SDS-PAGE. Proteins were transferred onto nitrocellulose filters
and immunoblotted with anti-ubiquilin pAb. In addition, various partial-
length GST–ubiquilin fusion proteins were constructed, expressed, and
purified using the GST-protein purification procedures described previ-
ously (Janicki and Monteiro, 1997). The specific subregions of ubiquilin
that were expressed are depicted in Fig. 2 III.
 
Rabbit pAb Production and Affinity Purification
 
Rabbit anti-ubiquilin polyclonal antisera were generated against purified
GST–ubiquilin fusion proteins B or C (Fig. 2 III) by Covance Research
Products, Inc. Affinity-purified anti–ubiquilin-C antibodies were obtained
by passing anti–C-serum first over a column containing GST alone cou-
pled to CH-Sepharose 4B beads at 4
 
8
 
C overnight, to eliminate antibodies
binding to GST, and then by mixing the flow-through fraction with ubiqui-
lin–coupled CH-Sepharose 4B beads at 4
 
8
 
C overnight. After extensive
washing, antibodies that bound to the ubiquilin-coupled beads were
eluted dropwise with 0.1 M sodium citrate and 0.3 M sodium chloride so-
lution, pH 2.2, and collected as 
 
z
 
240-
 
m
 
l fractions into tubes containing 40
 
m
 
l 1 M Tris-HCl, pH 9.1, to restore neutral pH.
 
In Vitro Transcription and Translation
 
[
 
35
 
S]Methionine-radiolabeled ubiquilin or luciferase proteins were synthe-
sized in rabbit reticulocyte lysates with an in vitro transcription and trans-
lation system (Promega) at 30
 
8
 
C for 90 min. [
 
35
 
S]Methionine-radiolabeled
PS2 and PS1 were synthesized using the same system, but with the addi-
tion of canine pancreatic microsomal membranes (Promega) during tran-
scription and translation.
 
GST Pull-down Binding Assay
 
Various purified GST–ubiquilin fusion proteins already bound to glu-
tathione-agarose beads were incubated with 
 
z
 
2.5 
 
m
 
l [
 
35
 
S]methionine-radio-
labeled presenilin protein, in addition to protease inhibitors and 0.8%
BSA at 4
 
8
 
C for 1 h with rocking. The beads were washed several times
with pull-down buffer (0.5% NP-40 in 1.0
 
3
 
 PBS), once with 200 mM KCl
in pull-down buffer, and several more times with pull-down buffer alone.
Supernatants and washes were discarded, whereas the bound proteins on
the beads were mixed with sample loading buffer (Janicki and Monteiro,
1999) and separated by SDS-PAGE. Then, the gel was stained with Coo-
massie blue to ensure equal loading of GST–ubiquilin fusion proteins. The
gels were dried and exposed to autoradiography film.
 
Mammalian Expression and Fusion Constructs
 
Full-length ubiquilin was expressed using the pGEM-CMV mammalian
expression vector (Janicki and Monteiro, 1997) (see Fig. 2 IV). In addi-
tion, two ubiquilin fusion proteins were constructed within the same ex-
pression vector. In one, green fluorescent protein (GFP) was fused to the
NH
 
2
 
 terminus of ubiquilin (beginning at residue 20 [Ala]), whereas in the
other, a myc epitope tag was fused to the COOH terminus of full-length
ubiquilin.
 
HeLa Cell Culture and DNA Transfection
 
HeLa cells were grown at 37
 
8
 
C in DME supplemented with 10% FBS and
transfected with plasmid DNAs, using the calcium phosphate coprecipita-
tion method.
 
Western Blot Analysis
 
Cells were lysed in buffer containing protease inhibitors (Monteiro and
Mical, 1996), and protein concentrations were determined by the bicin-
chonic acid (BCA) assay. Lysates containing known amounts of protein
were mixed with sample loading buffer (Janicki and Monteiro, 1999) and
 
either heated at 100
 
8
 
C for 5 min or at 37
 
8
 
C for 15 min before separation by
SDS-PAGE. The 37
 
8
 
C incubation was used to detect presenilin proteins
by minimizing their tendency to aggregate and resist entry into the gels.
After gel electrophoresis, proteins were transferred onto nitrocellulose fil-
ters and immunoblotted according to procedures described previously
(Janicki and Monteiro, 1997). In addition to our own rabbit anti-ubiquilin
antibodies, we also used the following primary antibodies: goat anti-PS1,
anti-PS2, and anti-BiP (NH
 
2
 
 terminus specific; Santa Cruz Biotechnology,
Inc.); rabbit anti-PS2 (NH
 
2
 
 terminus or loop specific, raised to the corre-
sponding GST–PS2 fusion proteins) (Janicki and Monteiro, 1997, 1999)
anti-ubiquitin (Dako), anti-lamin A/C (Mical and Monteiro, 1998), anti-
calnexin, and anti-calreticulin (StressGen); and mouse anti-GFP (Zymed
Laboratories), anti–
 
a
 
-tubulin (Sigma-Aldrich), and anti-lamin B (Matri-
Tect). Binding of primary antibodies were detected with 
 
125
 
I-protein A or
by incubation with appropriate secondary horseradish peroxidase–conju-
gated antibodies (New England Biolabs, Inc.) using autoradiography or
chemiluminescence, respectively.
 
Immunoprecipitation and Cell Fractionation Studies
 
HeLa cells, 17 h after transfection with PS2 plasmid DNA, were collected
in immunoprecipitation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.5% NP-40, 2 mM EDTA) and homogenized by gentle strokes with a
Dounce homogenizer. After centrifugation, the pellet was discarded, and
the proteins were immunoprecipitated from the remaining supernatant by
adding rabbit antisera (preimmune, anti–PS2-NH
 
2
 
 terminus, or anti–PS2-
Loop) and protein A–Sepharose CL-4B beads (Stabler et al., 1999). The
beads were recovered by centrifugation and washed with 0.5% NP-40 in
1.0
 
3
 
 PBS. They were boiled in sample loading buffer, and the bound pro-
teins were analyzed by SDS-PAGE and immunoblotting. Blots were
probed with primary anti–ubiquilin-B antibodies, which were subse-
quently detected with 
 
125
 
I-protein A. Soluble, insoluble, Triton X-100–sol-
uble, and Triton X-100–insoluble protein fractions of untransfected or
PS2-transfected HeLa cells were prepared according to the procedure de-
scribed previously (Stabler et al., 1999). Equal amounts of each fraction
were separated by SDS-PAGE and, after electroblot transfer to nitrocel-
lulose filters, were immunoblotted with either affinity-purified anti–
ubiquilin-C antibody, anti–PS2-NH
 
2
 
 terminus antibody, or anti-lamin A/C
antibody (Mical and Monteiro, 1998). The partitioning of endogenous
lamin A/C proteins was monitored, since their cell fractionation behavior
was known (Mical and Monteiro, 1998; Stabler et al., 1999).
 
Cell Staining and Immunofluorescence Microscopy
 
The procedure used for immunofluorescence staining of HeLa cells was
described previously (Janicki and Monteiro, 1997). Indirect immunofluo-
rescent microscopy, digital image capture, and subsequent manipulation
and merging of images were done with a Leica DM IRB microscope at-
tached to a PowerMac computer running Signal Analytics IPLab Spec-
trum software (Stabler et al., 1999). Confocal images were captured on a
Axiovert 100 microscope using LSM software (ZEISS). The primary anti-
bodies used were: rabbit anti–ubiquilin-B and affinity-purified anti–
ubiquilin-C, goat anti-PS1 and anti-PS2 (NH
 
2
 
 terminus specific) (Santa
Cruz Biotechnology, Inc.), and mouse anti-myc (Mical and Monteiro,
1998).
 
Human Brain Immunohistochemistry
 
Hippocampus brain tissue from six AD cases (aged 77–95) and five con-
trol cases (aged 19–71) were fixed in methacarn (6:3:1, chloroform/meth-
anol/acetic acid) overnight. Locus coreuleus or substantia nigra brain tis-
sue from three PD cases (aged 53–66) were fixed in formalin overnight,
whereas frontal cortex brain tissue from two cases of diffuse Lewy body
disease (aged 49 and 85) were fixed in either formalin or methacarn over-
night. Samples were dehydrated and embedded in paraffin. Sections were
cut 6-
 
m
 
m thick and mounted onto glass slides. After deparaffinization
with xylene, sections were hydrated through graded ethanol treatment,
and the endogenous peroxidase activity was eliminated by incubation in
3% hydrogen peroxide for 30 min. Nonspecific binding sites were
blocked with 10% normal goat serum in Tris-buffered saline (50 mM
Tris-HCl, 150 mM NaCl, pH 7.6) for 30 min before application of either
preimmune sera, affinity-purified anti–ubiquilin-C antibody, or anti–
ubiquilin-B antibody. Immunostaining was performed using the peroxi-
dase–anti-peroxidase method, with DAB as cosubstrate (Sternberger,
1986). Color images of the stained slides were captured using a Sony Dig-
ital Photo Camera DKC-5000 on a Nikon Eclipse E600 microscope using
Adobe Photoshop
 
®
 
 software. 
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Protein Accumulation Studies
 
HeLa cells were transfected with expression constructs encoding ubiquilin
protein (15 
 
m
 
g plasmid DNA), PS2 protein (7 
 
m
 
g plasmid DNA), or both.
At 12 h after transfection, the cells were incubated for an additional 5–6 h
in DME/FBS media in the absence or presence of proteasome inhibitors
(20 
 
m
 
M synthetic lactacystin or 40 
 
m
 
M MG-132; Calbiochem-Novabio-
chem). Afterwards, the cells were lysed in buffer containing protease in-
hibitors and the protein concentrations were determined. Protein extracts
totaling 100 
 
m
 
g were loaded per lane, separated by SDS-PAGE, and im-
munodetected with various antibodies. In a follow up experiment, HeLa
cells were cotransfected with a constant amount of PS2 (7 
 
m
 
g plasmid
DNA) and increasing amounts of either ubiquilin (0, 1, 2, 3, and 4 
 
m
 
g plas-
mid DNA) or GFP (0, 1, 2, 3, and 4 
 
m
 
g plasmid DNA) expression vectors.
 
Pulse-Chase Experiments
 
Exponentially growing HeLa cells maintained in flasks were trypsinized
and resuspended at a density of 2.68 
 
3
 
 10
 
6
 
 cells/ml in Opti-MEM medium
(GIBCO BRL). Two 0.5-ml aliquots of the cell suspension were each elec-
troporated with a mixture of either 7 
 
m
 
g PS2 and 15 
 
m
 
g of EGFP-C1
(CLONTECH Laboratories, Inc.) expression plasmid DNA or 7 
 
m
 
g PS2
and 15 
 
m
 
g of ubiquilin expression plasmid DNA. The aliquots containing
the same DNA mixture were then combined, resuspended in 28 ml of Op-
tiMEM medium (containing 10% FBS), and 2 ml of the suspension was
plated in 14 separate wells (9.5 cm
 
2
 
). The cells were incubated for 7 h to al-
low for attachment to the dishes, and then the medium was removed and
replaced with DME containing 10% FBS. Incubation was continued for
an additional 14 h. The cells were starved for 45 min in methionine-defi-
cient DME containing 10% dialyzed FBS. The medium was removed and
the cells in each well were pulse labeled by adding 1 ml of the methionine-
deficient medium containing 150 
 
m
 
Ci of [
 
35
 
S]methionine (1,000 Ci/mmol;
Amersham Pharmacia Biotech) for 1 h. After labeling, the cells were
washed twice with DME containing 1 mM nonradioactive 
 
L
 
-methionine
and 10% dialyzed FBS, and then they were chased with 2 ml of the same
medium for 0–6 h. At appropriate time intervals, the cells were washed
three times with ice-cold 1.0
 
3
 
 PBS and lysed in buffer containing protease
inhibitors (Monteiro and Mical, 1996). The lysates were diluted 10-fold
with immunoprecipitation buffer before PS2 proteins were immunopre-
cipitated, which was done by the addition of 5 
 
m
 
l rabbit anti-loop PS2 anti-
body (directed against GST-PS2 loop purified protein) (Janicki and Mon-
teiro, 1997) and 100 
 
m
 
l of a slurry of protein A–Sepharose (Amersham
Pharmacia Biotech). The immunoprecipitated proteins attached to the
Sepharose beads were eluted by incubation with protein sample loading
buffer (lacking SDS), which contained 8 M urea, 10 mM DTT, and 10%
 
b
 
-mercaptoethanol (Janicki and Monteiro, 1999), at 37
 
8
 
C for 15 min. The
entire volume of samples were separated by SDS-PAGE on 8.5% gels.
After electrophoresis, the gel was stained with Coomassie blue, impreg-
nated with 2,5-diphenyloxazole, and dried (Stabler et al., 1999). The ra-
dioactivity of the immunoprecipitated PS2 band in each lane, correspond-
ing to full-length PS2 protein, was quantified using a Molecular Dynamics
Storm 840 Phosphoimager using ImageQuant software (Molecular Dy-
namics).
The half-life of endogenous HeLa ubiquilin protein was estimated by
pulse labeling mock-electroporated HeLa cells for 1 h with 100 
 
m
 
Ci of
[
 
35
 
S]methionine, followed by a chase with nonradioactive medium for
0–21 h. Ubiquilin protein was immunoprecipitated using 5 
 
m
 
l of rabbit
anti–ubiquilin-C antibody, and the amount of radioactivity incorporated
in the ubiquilin bands was determined after SDS-PAGE and phosphoim-
age analysis.
 
Results
 
Identification of Human Ubiquilin, a Novel Interactor 
of the Presenilin Proteins
 
A novel human protein, which we named ubiquilin, for a
protein with ubiquitin-related protein domains that inter-
acts with the presenilins, was identified in a yeast two-
hybrid screen (Y2H) for proteins that interact with the PS2
COOH-terminal sequence (Fig. 1, A and B). Two overlap-
ping clones encoding the COOH-terminal 203 and 218 resi-
dues of ubiquilin were isolated in the screen. To clone the
entire ubiquilin ORF, 5
 
9
 
 RACE was performed. This
yielded 1,053 bps of additional upstream sequence, includ-
ing an in-frame methionine codon located at the beginning
of a ubiquitin-like (UB) domain. Conceptual translation
from this methionine predicted a 559-amino acid protein.
However, this methionine was unlikely to be the authentic
start codon since translation from it produced a protein that
was noticeably smaller, as seen by SDS-PAGE, than endog-
enous ubiquilin detected using pAb raised to the COOH-
terminal 218 residues of ubiquilin (data not shown). Subse-
quent EST database searches and sequencing of putative
overlapping clones yielded a clone with a longer 5
 
9
 
 end,
which included an upstream in-frame methionine codon
(corresponding to a 595-amino acid protein). Several lines
of evidence indicate that this methionine codon was the au-
Figure 1. Ubiquilin interacts with two different regions of prese-
nilin proteins. (A) A schematic diagram of ER-bound human
PS2 and shows eight transmembrane domains with its NH2 termi-
nus, large hydrophilic loop, and COOH terminus all protruding
into the cytoplasm. PS1 is believed to have a similar structure.
The presenilin loop region (Loop, in white) and COOH terminus
(striped) were used in Y2H assays. Two PS2 mutants used in this
study contained progressively longer COOH-terminal deletions:
PS2(DC), which terminated at the arrowhead, and PS2(DLC),
which terminated at the arrow. (B) The amino acid sequence of
PS1 and PS2 COOH terminus and loop regions that were used as
Y2H baits. (C) Y2H b-galactosidase liquid culture interaction as-
say of an ubiquilin-prey clone (Fig. 2 III, construct B without
GST) with PS2-COOH terminus (PS2-C), LexA alone, nuclear
lamin B, and CENP-C baits. The b-galactosidase units were nor-
malized to CENP-C, the bait with the weakest interaction. (D)
b-Galactosidase interaction assay data of a near full-length
ubiquilin-prey clone (Fig. 2 III, construct H without GST) re-
peated with the same baits described in C along with PS1-COOH
(PS1-C) terminus, PS2-Loop (PS2-L), and PS1-Loop (PS1-L)
baits. Again, b-galactosidase units were normalized to CENP-C. 
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thentic start methionine of ubiquilin. (a) This start methio-
nine contained a Kozak consensus sequence and an up-
stream in-frame stop codon. (b) Polypeptides translated
from this start codon matched the endogenous ubiquilin
protein in size, which was 66 kD in HeLa and other human
cell types. (c) Mammalian overexpression of the complete
ubiquilin ORF (see Fig. 3, D–F), in vitro transcribed and
translated ubiquilin in rabbit reticulocyte lysates (see Fig. 3
G), and human ubiquilin protein synthesized in bacteria
(see Fig. 3 H) all generated 66-kD proteins. These data in-
dicated that we had cloned the complete ubiquilin ORF
and that the protein is probably not extensively modified in
mammalian cells, since bacterially and eukaryotically ex-
pressed human ubiquilin proteins have similar molecular
masses when separated by SDS-PAGE.
Interaction between ubiquilin and the presenilins was
quantified in Y2H b-galactosidase liquid culture assays. A
partial ubiquilin clone (encoding the COOH-terminal 218
residues), isolated from the Y2H screen, and a near full-
length clone (encoding residues 37–595) both bound to the
PS2-COOH-terminal bait .55-fold compared with nega-
tive-control baits (Fig. 1, C and D, respectively). However,
the longer ubiquilin clone interacted less strongly with the
PS1–COOH-terminal bait. This interaction nevertheless
was still .12-fold compared with the negative-control baits
(Fig. 1 D). We also tested whether ubiquilin would interact
with portions of the loop regions of the presenilins (Fig. 1,
A and B) that we had used in another Y2H study (Stabler
et al., 1999). Interestingly, the near full-length ubiquilin
construct also interacted well with both PS2 and PS1 loop
sequences, and, surprisingly, the interaction was approxi-
mately twice as strong as with the PS2–COOH-terminal
bait (Fig. 1 D). This suggested that two separate regions
within the presenilin proteins could interact with ubiquilin.
The Gene for Ubiquilin Is Located on Chromosome 
9q22 and Is Widely Expressed
Northern blot analysis of human tissues indicated that
ubiquilin mRNA is widely expressed as a major 4.4-kb tran-
script, with several smaller differentially expressed minor
Figure 2. Schematic drawings of ubiquilin expression constructs.
(I) The full-length ubiquilin polypeptide consists of 595 residues
and contains an NH2-terminal UB domain (speckled), a COOH-
terminal UBA domain (striped), and several regularly spaced as-
paragine-proline (Asn-Pro) repeats (vertical bars). (II) The
probes used in human Northern blots. (III) GST-fusion con-
structs: A (N393–S595 aa), B (Q378–S595 aa), C (Q113–M377
aa), D (Q541–S595 aa), E (D449–S595 aa), F (D449–L540 aa), G
(N393–L540 aa), H (M37–S595 aa), I (M37–L540 aa), J (Q113–
L540 aa), K (Q113–S595 aa), and L (GST alone). The ubiquilin
portions of constructs A and B were isolated in the original Y2H
screen. Bacterially expressed GST–fusion B and C polypeptides
were used as immunogens for anti-ubiquilin pAb production (*).
(IV) Mammalian expression constructs: M, full-length untagged
ubiquilin; N, NH2-terminal GFP-tagged ubiquilin fused at residue
20 (Ala); and O, COOH-terminal myc epitope-tagged ubiquilin.
Figure 3. Ubiquilin mRNA and protein expression. (A) Human
multiple tissue were analyzed by Northern blot and probed
with ubiquilin cDNA fragment X (Fig. 2 II). After stripping,
the blot was reprobed with a b-actin control fragment (shown
below). (B) Northern blot of specific regions of the human
brain probed with ubiquilin cDNA fragment Y (Fig. 2 II), with
a reprobe with b-actin, which is shown below. (C) Quantifica-
tion of ubiquilin mRNA expression levels. Relative expression
of ubiquilin in different tissues was determined by densitomet-
ric analysis of the autoradiographs and relating the ubiquilin
band intensities to the levels of b-actin hybridization from the
same lanes. The values are presented after normalization
against skeletal muscle (above) and spinal cord (below). (D–F)
Characterization of anti-ubiquilin antibodies. Rabbit antibod-
ies were raised against GST–ubiquilin fusion proteins B and C,
generating anti-ubiquilin-B and anti–ubiquilin-C antibodies, re-
spectively. (D) Anti–ubiquilin-B antibody was used to detect
overexpressed and endogenous ubiquilin in ubiquilin trans-
fected, mock-transfected, and untransfected (endogenous)
HeLa cells. The anti–ubiquilin-B antibody detected a 66-kD
doublet band, whereas preimmune sera did not. (E) Anti–
ubiquilin-C antibody also recognized the 66-kD band in un-
transfected HeLa lysates and to varying extents a z55-kD band. HeLa cells transfected with GFP–ubiquilin (Fig. 2 IV, N) contain an addi-
tional 93-kD reactive band, due to the fusion of the 27-kD moiety of GFP with ubiquilin. (F) Affinity-purified anti–ubiquilin-C antibody
specifically reacts with the 66-kD band from transfected HeLa cell lysates. (G) Full-length in vitro transcribed and translated [35S]methio-
nine-radiolabeled human ubiquilin polypeptides migrated at 66 kD, whereas radiolabeled luciferase migrated at 61 kD. (H) Uninduced
and IPTG-induced lysates of bacteria transformed with untagged full-length human ubiquilin and probed with anti–ubiquilin-B antibodies.
Full-length immunoreactive ubiquilin (66 kD) and a series of smaller breakdown products are only seen in the induced lysate.The Journal of Cell Biology, Volume 151, 2000 852
Figure 4. Ubiquilin shares significant homology with several other proteins. The inferred amino acid sequence of the human ubiqui-
lin ORF and its homology to several related proteins: Homo sapiens Chap1, a protein involved in binding Hsp70-like Stch protein;
Mus musculus PLIC-1 and PLIC-2, proteins involved in linking integrins to vimentin; X. laevis XDRP1, a protein which binds cyclin
A; C. elegans F15C11.2 and two A. thaliana proteins, proteins with unknown functions; and S. cerevisiae DSK2, involved in spindle
pole body duplication. Identical residues are darkly shaded, whereas similar residues are lightly shaded. Only homology in five or
more sequences are shown. All the proteins contain UB domains (square box) and UBA domains (rounded box), which are ex-
tremely well conserved in sequence. In addition, the central region between the UB and UBA domains contain several asparagine-
proline repeats, which are either regularly spaced apart (closed circles) or located elsewhere throughout the protein (open circles).
The high overall homology of the proteins suggests that they belong to the same multigene family.Mah et al. Ubiquilin Modulates Presenilin Protein Accumulation 853
transcripts (Fig. 2 II, X; Fig. 3 A). Comparison of ubiqui-
lin band intensities after correction for mRNA loading
(b-actin control bands) and normalized to the skeletal mus-
cle value suggested that expression of the 4.4-kb transcript
was highest in brain and pancreas (Fig. 3 C). Additional
Northern blot analysis of mRNA from different subregions
of the human brain revealed slight variation (1.0–1.5-fold)
of ubiquilin expression with the same 4.4-kb transcript as
the predominant species (Fig. 2 II, Y; Fig. 3, B and C).
We determined the chromosomal location of the ubiqui-
lin gene using PCR radiation hybrid mapping (see Materi-
als and Methods; data not shown). This procedure resulted
in an unambiguous assignment of ubiquilin nearby to two
loci, CHLC.GATA22H04 and CHLC.GATA81C04, lo-
cated on chromosome 9q22 close to the 9q21.3 border. In-
terestingly, the chromosome region to which ubiquilin
maps is thought to contain a susceptibility gene(s) in-
volved in late-onset AD (Kehoe et al., 1999).
Ubiquilin Contains Ubiquitin-related Protein Domains 
and Is a Member of a Highly Conserved Gene Family
The complete ubiquilin ORF consists of 595 residues, with
a sequence rich in glutamines and serines, 10.9% and
11.1%, respectively, but lacking any cysteines (Fig. 4). The
protein has a calculated isoelectric point (pI) of 4.97 and is
predicted to be soluble, based on having a high hydrophilic
profile using MacVector 6.5 software (Oxford Molecular
Group; data not shown). Currently known protein struc-
tural motifs residing within ubiquilin include an NH2-ter-
minal UB domain and a COOH-terminal ubiquitin-associ-
ated (UBA) domain, both of which have been implicated
in targeting and degradation of proteins by the ubiquitin-
proteasome pathway. The predicted ubiquilin protein also
contains numerous regularly spaced asparagine-proline
(Asn-Pro) repeats of unknown function (Fig. 4). When
first sequenced, no apparent mammalian homologue for
ubiquilin had been deposited in GenBank/EMBL/DDBJ
databases. However, there was significant homology to
several full-length genes of unknown function: the C. ele-
gans F15C11.2 gene (36% identical) and two related genes
in Arabidopsis thaliana (34 and 35% identical). In addi-
tion, the protein had weak homology to the Saccharomyces
cerevisiae DSK2 gene (31% identical), which can suppress
a KAR1 defect (Biggins et al., 1996). KAR1 is an essential
gene involved in the duplication of the yeast microtubule
organizing center known as the spindle pole body. Interest-
ingly, ubiquilin homology to DSK2 was primarily confined
to the UB and UBA domains. However, since both UB
and UBA domains are present in many other proteins, it is
uncertain whether ubiquilin and DSK2 are true orthologs.
At about the time the ubiquilin sequence was deposited
in GenBank/EMBL/DDBJ, a Xenopus laevis protein in-
volved in inhibiting cyclin A–protein degradation, called
XDRP1, and having 60% identity to ubiquilin had just
been submitted (Funakoshi et al., 1999). Since then, two
Mus musculus proteins that are thought to interlink inte-
grin-associated proteins with the vimentin cytoskeleton,
called PLIC-1 and PLIC-2 (84 and 69% identical, respec-
tively) (Wu et al., 1999), and human Chap1 protein (re-
named ubiquilin 2; 79% identical), which binds Hsp70-
like Stch and can complement a DSK2 yeast mutant
(Kaye et al., 2000), have been described. The high degree
of homology among these protein sequences can be seen
when aligned by the MacVector 6.5 ClustalW protein
alignment program (Fig. 4). This comparison revealed
that the human, mouse, and Xenopus sequences are more
closely related to one another than the C. elegans, A.
thaliana, and S. cerevisiae sequences, as would be ex-
pected for higher eukaryotes. The former group of pro-
teins all shared extensive homology across the entire
length of the ubiquilin polypeptide. The four regions of
highest homology include the UB and UBA domains and
Figure 5. Ubiquilin binds presenilins in vitro. (A and B) GST
pull-down experiments. Full-length in vitro synthesized 35S-labeled
PS2 and PS1 (first lanes) migrated in SDS-PAGE gels with
broad bands of 54 and 48 kD (arrowheads), respectively, along
with a smear of slower migrating forms, presumably due to the
highly hydrophobic nature of the proteins. [35S]PS complexes
(especially the slower migrating forms) were retained by GST–
ubiquilin constructs containing the UBA domain (lane letters
correspond to constructs shown in Fig. 2 III), but not by those
lacking the domain, or by GST alone. (C) Immunoprecipitation
experiments. PS2-transfected HeLa cell lysates were immuno-
precipitated with preimmune sera or corresponding anti–PS2-
Loop antibody and anti-PS2 NH2 terminus antibody. After sepa-
ration by SDS-PAGE, coprecipitating ubiquilin (arrowhead)
was detected by immunoblotting with anti–ubiquilin-B antibody.
(D–F) Cell fractionation experiments. Parallel immunoblots of
equal portions of soluble supernatant (S) and insoluble pellet (P)
HeLa cellular fractions prepared without the use of detergent
(2) or in the presence of 1% Triton X-100 (1) with (D and F)
anti-ubiquilin or (E) anti-PS2 antibodies. The HeLa cells used
for cell fractionation in D were untransfected, whereas, in E and
F, the cells were transfected with a full-length wild-type PS2 con-
struct. The relative ratio of ubiquilin protein in the P2 compared with the S2 fractions was determined by densitometric analysis of the auto-
radiographs. This analysis indicated that transfection of presenilin caused 30% more (F) ubiquilin protein to partition in the pellet fraction in
the absence of detergent compared with (D) untransfected cells. The partitioning of lamin A/C proteins after cell fractionation from untrans-
fected and PS2-transfected cells was monitored with anti-lamin A/C antibodies and shown below in D and F, respectively.The Journal of Cell Biology, Volume 151, 2000 854
two stretches rich in Asn-Pro repeats (residues G157–
P326 and P375–P482) located between the two ubiquitin-
related domains. Differences in the divergent regions are
instructive, especially the insert between residues L485–
T527 in Chap1, which is conserved in PLIC-2 but missing
in ubiquilin, PLIC-1, and XDRP1. Based on the homol-
ogy between human and mouse sequences, it appears that
ubiquilin is more closely related to PLIC-1, whereas
Chap1 is more closely related to PLIC-2. Collectively, the
proteins are likely to be members of a related multigene
family, since at least two independent genes are known to
exist in humans, mice, and A. thaliana.
Figure 6. Ubiquilin localizes to the nucleus and cytoplasm. (A, B, D, and E) Indirect immunofluorescence microscopy of endogenous
ubiquilin staining in untransfected HeLa cells and (C and F) confocal microscopy of HeLa cells transfected with ubiquilin or (I) myc-
tagged ubiquilin. (A and B) Preimmune and the corresponding anti–ubiquilin-B antibody staining, respectively, are shown. (C) Overex-
pressed ubiquilin as detected with anti–ubiquilin-B antibody. (D and E) Preimmune and the corresponding anti–ubiquilin-C antibody
staining, respectively, are shown. (F) Overexpressed ubiquilin is shown, as detected with affinity-purified anti–ubiquilin-C antibody.
Both anti-ubiquilin sera showed specific staining in the cytoplasm and nucleus, along with cytoplasmic punctate structures in a subset of
the untransfected cells (arrows). The expression levels of ubiquilin protein within the nucleus varied with some cells containing substan-
tially more nuclear protein (arrowheads). Transient overexpression of wild-type ubiquilin caused frequent accumulation of ubiquilin to
the intracellular punctate structures. (G) Endogenous ubiquilin is shown, as detected by affinity-purified anti–ubiquilin-C antibody
(confocal microscopy). (H) Overexpressed GFP-tagged ubiquilin of live HeLa cells, as seen by fluorescence microscopy, revealed accu-
mulation of the fusion protein to the cytoplasm and to similar punctate structures. (I) Additional evidence for intracellular localization
of ubiquilin, using a myc-tagged construct and stained with an anti-myc mAb (confocal microscopy), is shown. Bar, 25 mm.Mah et al. Ubiquilin Modulates Presenilin Protein Accumulation 855
Evidence That Ubiquilin Protein Directly Binds 
PS1 and PS2
GST-fusion proteins containing the UBA domain and nine
COOH-terminal residues (QHHSSISVS) of ubiquilin were
necessary and sufficient to bind [35S]methionine-radio-
labeled PS2 and PS1 in a GST pull-down assay (Fig. 5, A
and B, respectively). Interestingly, slower migrating forms
of both presenilins were much more tightly bound than the
full-length forms. Whether the slower migrating forms are
more ubiquitinated, extensively modified, or merely hy-
drophobic aggregates is not known. As expected, GST
alone (Fig. 5, A and B, lane L) did not bind either preseni-
lin. No other region of ubiquilin tested was able to pull-
down either of the presenilins, indicating that binding of
presenilin to ubiquilin is mediated by sequences spanning
the UBA domain and the COOH-terminal tail. These in
vitro binding assay results were consistent with the interac-
tion data of ubiquilin recovered in the Y2H screen.
To support the in vitro binding data, coimmunoprecipi-
tation and cell fractionation experiments between PS2 and
endogenous ubiquilin were also performed. PS2-trans-
fected HeLa cell extracts were immunoprecipitated with
two different anti-PS2 specific antibodies, separated by
SDS-PAGE, and immunoblotted with anti–ubiquilin-B
antibodies. Ubiquilin protein coimmunoprecipitated with
both of the anti-PS2 antibodies, one raised against the
loop and the other to the NH2-terminal sequences, but did
not coimmunoprecipitate when the preimmune sera was
used (Fig. 5 C). Additional verification of ubiquilin bind-
ing to PS2 was obtained in cell fractionation studies. Un-
transfected and PS2-transfected HeLa cells were fraction-
ated either in the absence or presence of Triton X-100
detergent into soluble and insoluble fractions. Equivalent
amounts of the fractions were then immunoblotted to de-
termine the amount of ubiquilin protein in the two frac-
tions. In untransfected cells, almost all of the ubiquilin
protein was present in the soluble fraction, independent of
detergent treatment (Fig. 5 D, lanes S2 and S1). This is
consistent with the predicted hydrophilic nature of ubiqui-
lin protein. However, in PS2-transfected cells, 30% more
ubiquilin protein separated with the pellet fraction in the
absence of detergent treatment (Fig. 5 F, lane P). This
change in solubility is likely a consequence of ubiquilin
binding to overexpressed membrane-bound PS2, which
also fractionated in the insoluble membrane-containing
pellet fraction (Fig. 5 E, lane P2). As expected for integral
membrane proteins, Triton X-100 treatment caused the re-
lease of PS2 into the soluble fraction (Fig. 5 E, lane S1),
which coincided with ubiquilin once again separating com-
pletely in the soluble fraction (Fig. 5 F, lane S1).
Ubiquilin Localizes To the Nucleus and Cytoplasm
To determine the intracellular distribution of ubiquilin we
used rabbit pAb that we had generated to two different
GST–ubiquilin fusion proteins (see Materials and Meth-
ods). Both antisera detected endogenous and overex-
pressed 66-kD ubiquilin polypeptides, which were not de-
tected by the preimmune sera (Fig. 3 D). Although one
antiserum reacted with an unknown protein of z55 kD
(Fig. 3 E), this reactivity was subsequently removed by af-
finity purification of the antibody (Fig. 3 F). Immunofluo-
rescence staining of ubiquilin within cells was performed
with the specific anti-ubiquilin antibodies. Compared with
the preimmune sera (Fig. 6, A and D), both antibodies re-
vealed similar staining patterns (Fig. 6, B and E). Indirect
immunofluorescence, as well as laser confocal microscopy,
revealed endogenous intracellular localization of ubiquilin
in HeLa cells to both the nucleus and cytoplasm (Fig. 6, B,
E, and G). In some cells, endogenous ubiquilin staining
was stronger in the nucleus (Fig. 6 E, arrowheads). Fur-
thermore, in a small subset of cells, ubiquilin within the cy-
toplasm was localized to punctate structures (Fig. 6, B and
E, arrows). The frequency of these structures dramatically
increased upon overexpression of full-length untagged
ubiquilin (Fig. 6, C and F). To corroborate the anti-ubiqui-
lin staining pattern, we performed additional localization
studies on myc- and GFP-tagged ubiquilin proteins in
HeLa cells (Fig. 2 IV, O and N, respectively). Overex-
pressed myc-tagged ubiquilin stained with anti-myc mAb
exhibited the same intracellular structures (Fig. 6 I) as
overexpressed wild-type ubiquilin (Fig. 6, C and F). Fi-
nally, the same fluorescent staining pattern was repro-
duced upon overexpression of GFP-ubiquilin (Fig. 6 H).
Since the GFP-ubiquilin image in Fig. 6 H was captured
from live and unfixed cells without antibodies, this estab-
lished that the anti-ubiquilin structures seen previously
were not artifacts of the paraformaldehyde fixation or im-
munofluorescence staining procedures.
Intracellular Colocalization of the Presenilin and 
Ubiquilin Proteins
As overexpressed presenilin proteins are localized predom-
inantly to the ER, and ubiquilin protein in HeLa cells is
found throughout the nucleus and cytoplasm, we deter-
mined if ubiquilin colocalized with the presenilins when the
latter were overexpressed. Indeed, there was a dramatic
change in ubiquilin staining in HeLa cells coexpressing ei-
ther PS1 or PS2 and ubiquilin, resulting in almost complete
colocalization of the presenilin and ubiquilin intracellular
staining patterns, as seen by laser confocal immunofluores-
cence microscopy (Fig. 7, A and B). Careful examination of
the colocalized proteins revealed ubiquilin staining to be
punctate, whereas presenilin staining could be traced to an
ER-like pattern. Particularly striking was colocalization of
ubiquilin with irregularly shaped presenilin-enriched struc-
tures within the cytoplasm of overexpressing cells. In con-
trast, there was little colocalization in the nucleus where
ubiquilin, but not presenilin, staining could be found.
Since Y2H data suggested that ubiquilin interacts with
both the loop and COOH-terminal domains of the prese-
nilins, we examined whether removal of these regions
from PS2 would abolish colocalization of the proteins in
vivo. To assess this possibility, two PS2 constructs con-
taining progressively longer COOH-terminal deletions
were made. In the first, PS2(DC), the 39-amino acid
COOH-terminal domain was deleted (Fig. 1 A, arrow-
head), whereas in the second, PS2(DLC), the large hydro-
philic loop and all sequences downstream were deleted
(Fig. 1 A, arrow). When expressed in HeLa cells,
PS2(DC) still colocalized with ubiquilin (Fig. 7 C), pre-
sumably since the PS2 loop region that remained could
bind ubiquilin, as suggested by the strong interaction be-
tween the two in Y2H assays (Fig. 1 D). However, onceThe Journal of Cell Biology, Volume 151, 2000 856
Figure 7. Intracellular colocalization between ubiquilin and the presenilins. (A–D) HeLa cells were cotransfected with ubiquilin and
either (A) wild-type PS1, (B) wild-type PS2, (C) PS2(DC) deletion mutant, or (D) PS2(DLC) deletion mutant and costained with ap-
propriate goat anti-presenilin antibodies (left images) and affinity-purified rabbit anti–ubiquilin-C antibody (center images). The
green (fluorescein) and red (rhodamine) confocal images in each row were merged and shown on the right, with yellow indicating
colocalization of ubiquilin and presenilin proteins. Bar, 10 mm.Mah et al. Ubiquilin Modulates Presenilin Protein Accumulation 857
the hydrophilic loop region and COOH terminus were
both removed, PS2(DLC) no longer colocalized with
ubiquilin (Fig. 7 D), suggesting that the NH2 terminus and
the first six transmembrane domains of PS2 do not con-
tain additional ubiquilin binding sites. A notable feature
of the overexpression of PS2(DLC) was its accumulation
into large spherical aggregates that failed to stain posi-
tively for ubiquilin.
Ubiquilin Expression Promotes Increased 
Accumulation of Presenilin Proteins
Since ubiquilin contains multiple ubiquitin-related struc-
tural motifs, we investigated whether its association with
presenilin would have an effect on presenilin-protein
modification and/or stability. Treatment of mock-trans-
fected and PS2-transfected HeLa cells with proteasome
inhibitors lactacystin (20 mM) or MG-132 (40 mM), as ex-
pected, increased the overall amount of ubiquitinated
proteins in cells (Fig. 8 A, lanes 2 and 3, 5 and 6, and 8
and 9 versus lanes 1, 4, and 7, respectively). However,
these conditions did not markedly increase PS2 protein
levels (Fig. 8 B, lanes 4–6). Remarkably, coexpression of
ubiquilin with PS2 caused a substantial (.10-fold) in-
crease in PS2 protein accumulation (Fig. 8 B, lanes 7–9)
compared with overexpression of PS2 alone (Fig. 8 B,
lanes 4–6). This effect was independent of treatment with
lactacystin or MG-132, as it also occurred just as robustly
in cells not treated with the proteasome inhibitors. Par-
ticularly striking was the increased accumulation in SDS-
PAGE gels of full-length uncleaved PS2 protein (Fig. 8
B, arrowhead) and higher molecular weight complexes
that PS2 forms. Increasing the amount of transfected
ubiquilin plasmid DNA, whereas maintaining constant
levels of transfected PS2 plasmid DNA, revealed a dose-
dependent effect by ubiquilin on PS2 accumulation
within the cells (Fig. 8 E, lanes 1–5). This effect was spe-
cific for ubiquilin expression, since cotransfection of in-
creasing amounts of GFP plasmid DNA with PS2 did not
increase PS2 protein accumulation (Fig. 8 F, lanes 1–5).
The blot in Fig. 8 E was exposed for a shorter time than
that in Fig. 8 F to optimally illustrate the subtle changes
in PS2 protein levels. In these experiments, we routinely
observed the accumulation of full-length PS2 protein, but
not the endoproteolytic cleaved forms of the protein
(Haass and De Strooper, 1999). In fact, recent reports
have indicated that cleavage of presenilins is not essential
for biological function of the presenilins, namely by its
ability to rescue PS activity in C. elegans (Jacobsen et al.,
1999; Steiner et al., 1999). The absence of detectable en-
doproteolytic cleaved forms of PS2 is more clearly illus-
trated in Fig. 8 G, which shows that an antibody specific
for PS2-loop sequences downstream of the proposed en-
doproteolytic cleavage site recognized the same 54 kD
and higher PS2 species (as the PS2 NH2-terminal specific
antibody). Interestingly, though ubiquilin caused a dose-
dependent increase in presenilin accumulation, it did not
alter the accumulation levels of various other endoge-
nous HeLa proteins, such as lamin B, calreticulin, cal-
nexin, BiP, and a-tubulin (Fig. 8 H). Similar experiments
repeated with PS1 indicated that ubiquilin also promoted
a dose-dependent increase in PS1 protein accumulation
in HeLa cells (data not shown).
Figure 8. Ubiquilin promotes increased PS2 pro-
tein accumulation. (A–D) HeLa cells, 12 h after
transfection with ubiquilin (15 mg expression plas-
mid, lanes 1–3), PS2 (7 mg expression plasmid,
lanes 4–6), or both (lanes 7–9), were either left un-
treated (lanes 1, 4, and 7) or treated for 5–6 h with
proteasome inhibitors (20 mM synthetic lactacys-
tin in lanes 2, 5, and 8; 40 mM MG-132 in lanes 3,
6, and 9). Equivalent amounts of protein (100 mg)
from each sample were immunoblotted with (A)
anti-ubiquitin, (B) anti-PS2-NH2 terminus, (C) af-
finity-purified anti–ubiquilin-C, or (D) anti-a-tubu-
lin antibodies. As expected, anti-ubiquitin anti-
bodies detected larger molecular weight proteins
in cells treated with proteasome inhibitors (lanes
2 and 3, 5 and 6, and 8 and 9) compared with un-
treated cells (lanes 1, 4, and 7). Significantly more
PS2 protein (and slower migrating forms) could
be seen in cells cotransfected with ubiquilin (lanes
7–9, arrowhead) compared with those transfected
with PS2 alone (lanes 4–6). (*) A doublet of
weakly reactive bands was detected in all lysates,
but we considered them to be nonspecific pro-
teins. The anti–a-tubulin blot shows equal protein
loading of each sample. (E) HeLa cells were
transfected with PS2 alone (9 mg expression plasmid, lane 1) or cotransfected along with increasing amounts of ubiquilin (1, 2, 3, or 4 mg ex-
pression plasmid in lanes 2–5, respectively). Equivalent amounts of the transfected lysates were separated through an 8.5% polyacrylamide
gel and immunoblotted with anti–PS2-NH2 terminus antibody. (F) Same as in E, except with the same increasing amounts of GFP expres-
sion plasmid (lanes 2–5) instead of ubiquilin. (G) Same as in E, but proteins were separated on a 10% polyacrylamide gel and immunoblot-
ted with anti–PS2-loop antibody. Note the absence of any detectable PS2 cleavage products corresponding to endoproteolytic PS2 cleavage
in the loop. (H) The same blot shown in G or parallel blots were immunoblotted for lamin B, calreticulin, calnexin, BiP, and a-tubulin. The
relative levels of these other endogenous proteins remained relatively unchanged compared with the PS2 levels.The Journal of Cell Biology, Volume 151, 2000 858
Ubiquilin Facilitates Increased PS2 Expression but 
Does Not Dramatically Alter PS2 Protein Turnover
To determine if the ubiquilin-induced increase in presenilin
accumulation is due to a change in the rate of presenilin pro-
tein turnover, we carried out pulse-chase experiments of
HeLa cells in which PS2 protein was coexpressed with either
ubiquilin or GFP (as a control). PS2 protein in the pulse-
chase lysates was immunoprecipitated using an anti–PS2-
loop antibody and resolved by SDS-PAGE (Fig. 9 A). Phos-
phoimage analysis of the immunoprecipitated full-length
PS2 band (z54 kD), indicated that the half-life of PS2 pro-
tein to be approximately similar. 3.1 and 2.9 h when coex-
pressed with GFP or ubiquilin, respectively (Fig. 9, A and
B). Apart from the prominent PS2 band at 54 kD, a smear of
bands with varying intensity was resolved after SDS-PAGE,
using the PS2-loop antibody for immunoprecipitation. Some
of these bands appear to be PS2 related, especially the
higher molecular weight species, as they corresponded to
similar PS2 immunoreactive species using this and other PS2
antibodies (Fig. 8, E and G) (Janicki and Monteiro, 1997,
1999). Phosphoimage analysis of the smear of bands above
the 97-kD marker indicated that the rate of turnover of these
larger PS2 complexes was also similar in both GFP- and
ubiquilin-coexpressing cells (data not shown).
A notable difference of these pulse-labeling experi-
ments was the increased amount of immunoprecipitated
PS2-labeled proteins in cells that were overexpressing
ubiquilin, compared with GFP. Despite using similar
amounts of PS2 DNA for electroporation within parallel-
labeling experiments, we routinely obtained a 1.6–2.0-fold
increase in PS2-labeled protein when PS2 was coexpressed
with ubiquilin compared with GFP. This effect was seen in
three separate experiments (data not shown). Overall,
these results suggest that the ubiquilin-induced elevation
in presenilin accumulation does not involve a substantial
change in the rate of presenilin–protein turnover, but in-
stead may facilitate increased PS2 protein synthesis. Fi-
nally, to determine the rate of endogenous ubiquilin
protein turnover, we performed another pulse-chase ex-
periment of mock-transfected HeLa cells and immunopre-
cipitated the endogenous ubiquilin protein using our anti–
ubiquilin-C antibody (Fig. 9 C). Phosphoimage analysis
indicated that pulse labeled ubiquilin decays exceedingly
slowly, only 15% over the 21 h chase period, from which
we estimate the half-life of the protein to be 90 h.
Immunohistochemistry of Human Brain Tissue 
Sections Reveals Ubiquilin Immunoreactivity in 
Neurons As Well As within Neuropathological Lesions 
Such As Neurofibrillary Tangles and Lewy Bodies
Since neuropathological lesions in AD and PD have been
found to be highly immunoreactive to ubiquitin antibodies,
we investigated whether these structures may also contain
ubiquilin immunoreactivity. Immunohistochemistry of adult
human brain sections was performed with anti–ubiquilin-B
and anti–ubiquilin-C antibodies. The former was raised
against ubiquilin polypeptides that were devoid of the UB
domain, whereas the latter was raised against ubiquilin
polypeptides lacking the UBA domain as well (Fig. 2 III, B
and C, respectively). Compared with the preimmune sera,
which showed no specific staining (Fig. 10, A and C), both
antibodies strongly stained neurons with little, if any, staining
of glia (Fig. 10, B, D, and E). In general, the anti–ubiquilin-C
antibody stained neurons with greater clarity and intensity.
As with cultured cells, anti-ubiquilin staining in neurons was
to the nucleus and the cytoplasm. In addition, there is clear
evidence for ubiquilin staining within long axonal processes
(Fig. 10 D). Interestingly, neurons containing neurofibrillary
tangles (NFTs) from AD affected brains seemed to stain
more intensely compared with control neurons (Fig. 10 E and
F). Moreover, examination of ubiquilin staining in brains af-
flicted with PD (not shown) and diffuse LB disease revealed
robust staining of Lewy bodies (Fig. 10 H).
Figure 9. Ubiquilin facilitates increased presenilin protein expres-
sion but does not substantially change presenilin protein turnover.
(A) HeLa cells, electroporated with a mixture of either PS2 and
GFP expression plasmids (7 mg PS2 and 15 mg pEGFP-C1) or with
PS2 and ubiquilin expression plasmids (7 mg PS2 and 15 mg
ubiquilin), were pulse labeled with [35S]methionine for 1 h and
then chased with nonradioactive medium for 0–6 h. At appropri-
ate time intervals (indicated above each lane), the cells were lysed
and PS2 protein was immunoprecipitated using a rabbit anti–PS2-
loop antibody. The immunoprecipitated proteins were separated
by SDS-PAGE through an 8.5% gel, and the radioactivity of the
band corresponding to full-length PS2 (arrowhead) in each lane
was determined by phosphoimage analysis. (*) The light band was
probably a nonPS2 related protein whose radioactivity changed
little during the chase period of the experiment and was therefore
useful for normalizing protein amounts loaded in each lane. (B)
Graph showing an exponential decline of pulse-labeled PS2 pro-
tein over time. The calculated half-life of PS2 in this experiment
was z3.1 and 2.9 h when coexpressed with GFP or ubiquilin, re-
spectively. In this and in two other experiments, z1.4–1.6-fold
more PS2 protein was synthesized (after normalization) when co-
expressed with ubiquilin than with GFP. (C) Mock-electroporated
HeLa cells were pulse labeled with [35S]methionine for 1 h and
then chased with nonradioactive medium for 0–21 h. Ubiquilin
protein was immunoprecipitated from the lysates using rabbit
anti–ubiquilin-C antibodies. The radioactivity of the immunopre-
cipitated ubiquilin band was determined by phosphoimage analy-
sis. This analysis revealed a small decline in radioactivity (15% re-
duction) over 21 h, indicating that the endogenous ubiquilin in
HeLa cells is long-lived, with an estimated half-life of z90 h.Mah et al. Ubiquilin Modulates Presenilin Protein Accumulation 859
Figure 10. Anti-ubiquilin staining of human brain tissue reveals strong staining of neurons in human brain and robust staining of NFTs and
Lewy bodies of AD and PD, respectively. Sections of human brain were stained with either the preimmune or anti–ubiquilin-B and anti–
ubiquilin-C antibodies. (A–D) Consecutive sections of the hippocampus of an AD afflicted brain were stained with either the (A and C) pre-
immune serum or with their corresponding (B) anti–ubiquilin-B and (D) anti–ubiquilin-C antibodies. (E and F) Examples of strong staining of
NFTs (arrows) in hippocampal sections of AD afflicted brains with anti–ubiquilin-C antibodies. (G) Anti–ubiquilin-C antibody staining of a
control nonAD human brain showing strong staining of neurons. (H) Cortical human brain section of a DLBD afflicted brain showing strong
anti–ubiquilin-C staining of Lewy bodies (arrows). Bars: (A–D and G and H) 40 mm; (E and F) 20 mm.The Journal of Cell Biology, Volume 151, 2000 860
Discussion
Here, we describe a novel human presenilin-interacting
protein named ubiquilin. Y2H interaction, GST pull-down
experiments, coimmunoprecipitation studies, changes in
the cellular fractionation of proteins, and colocalization of
the proteins expressed in vivo provide compelling evi-
dence that ubiquilin and the presenilins interact with one
another. Ubiquilin is an important protein because it con-
tains multiple ubiquitin-related domains typically thought
to be involved in targeting proteins for degradation, yet
ubiquilin promotes increased presenilin protein accumula-
tion. Moreover, ubiquilin is highly expressed in neurons of
human brain and is associated with NFTs and Lewy bodies
of AD and PD brains, respectively.
The promotion of presenilin protein accumulation by
ubiquilin overexpression is noteworthy as a new means by
which presenilin levels may be modulated. By conducting
pulse-chase experiments, we found that ubiquilin induced
an increase in presenilin protein maturation, but did not
dramatically affect presenilin protein turnover. The net ef-
fect over time from increased presenilin protein synthesis
and undisturbed turnover rate would eventually lead to an
elevation of the intracellular pool of presenilin proteins.
This modulation of presenilin levels by ubiquilin may have
important consequences to cellular functions, as presenilins
have been linked to various biological processes, including
Notch signaling, calcium regulation, apoptosis, cell cycle
regulation, unfolded-protein response, as well as APP-asso-
ciated gamma secretase activity (see Introduction).
It will be interesting to determine the precise mecha-
nism by which ubiquilin induces increased presenilin pro-
tein synthesis. Ubiquilin could increase presenilin synthe-
sis by simply increasing presenilin transcription, increasing
presenilin translation, or facilitating correct polypeptide
folding, maturation, and intracellular targeting of the poly-
topic transmembrane presenilin protein. Based on its vari-
ous properties, we are especially intrigued by the possibil-
ity that ubiquilin may act as a molecular chaperone. (a)
Studies of the Xenopus ubiquilin homologue, XDRP1,
have suggested that ubiquilin can act posttranscriptionally
like a molecular chaperone and prevent degradation of in
vitro translated cyclin A protein (Funakoshi et al., 1999).
(b) Chap1 (ubiquilin 2) has been shown to bind Stch, an
Hsp70-like protein (Kaye et al., 2000). In turn, many heat-
shock proteins have been shown to function as molecular
chaperones, preventing protein aggregation and protein
degradation (Warrick et al., 1999; Krobitsch and Lind-
quist, 2000). (c) Recent evidence has linked ubiquilin pro-
teins to the proteasome (Kleijnen et al., 2000). Meanwhile,
the 19S regulatory subunit of the 26S proteasome (the
degradation complex for ubiquitin-tagged proteins) has
been shown to possess protein-unfolding activity (Braun
et al., 1999). (d) Indirect evidence that ubiquilin may aid in
presenilin protein folding or targeting comes from our ob-
servation that the presenilin construct PS2(DLC), with de-
letions of both the loop and COOH-terminal ubiquilin-
interaction sites (as demonstrated by Y2H assays and lack
of colocalization with ubiquilin within cells), frequently ac-
cumulated into large cytoplasmic aggregates. In contrast,
presenilin molecules, which contained ubiquilin interac-
tion sites, rarely formed large protein aggregates. The con-
nection between aggregate accumulation and loss of
ubiquilin interaction may be entirely coincidental. How-
ever, the possibility that the two are interconnected cannot
be discounted. Finally, presenilins proteins have them-
selves been linked to molecular chaperones of the ER,
which are involved in the unfolded-protein response
(Katayama et al., 1999; Niwa et al., 1999).
Another mechanism by which ubiquilin might increase
presenilin accumulation is to alter presenilin degradation
rates, especially that of the ubiquitinated forms of preseni-
lins. In fact, a recent report by Kleijnen et al. (2000) found
evidence that overexpression of human ubiquilin proteins,
hPLIC-1 (ubiquilin 1) and hPLIC-2 (ubiquilin 2), inter-
fered with ubiquitin-dependent degradation of p53 and
IkBa. Although we did not find any significant change in
the turnover rate of the major 54-kD PS2 polypeptide spe-
cies (corresponding to full-length PS2), we cannot exclude
the possibility that certain ubiquitinated forms of preseni-
lins may have altered turnover rates. The ubiquitinated
forms of presenilins migrated as a smear on the SDS-
PAGE gels, which made quantification of the turnover
rates of these species difficult. It will be important in fu-
ture studies to determine if ubiquilin is involved in ubiq-
uitin-dependent degradation of presenilins.
The region in ubiquilin that binds presenilins was
mapped to the COOH-terminal region containing the
UBA domain, which is highly conserved in ubiquilin family
members from human to yeast (Fig. 4). This sequence was
both necessary and sufficient to bind PS1 and PS2 in vitro.
The UBA domain is a recently recognized motif present in
one or two copies in a variety of proteins involved in the
ubiquitin/proteasome folding/degradation pathway, UV
excision repair, and phosphorylation (Hofmann and
Bucher, 1996). The UBA domain consists of z55 total res-
idues of which 45 appear to be core residues. 15 of the core
residues are extremely well conserved, suggesting they
may be important for determining the overall structure of
the domain. Through nuclear magnetic resonance, the
structure of the COOH-terminal UBA domain of the hu-
man DNA repair protein HHR23A (RAD23 homologue)
has been determined. It is a compact three-helix bundle
with an exposed hydrophobic surface predicted to be in-
volved in protein–protein interactions (Dieckmann et al.,
1998). The strong binding of the ubiquilin UBA domain to
presenilins may be facilitated by similar protein–protein in-
teractions. It will be important to determine if sequence
variation of the UBA domain in different proteins influ-
ences binding specificity to different target proteins.
In vitro binding assays indicated that the UB domain in
the NH2-terminal portion of ubiquilin was not required for
binding presenilins. Although this domain shares high ho-
mology to the conserved 76-amino acid ubiquitin polypep-
tide, it is unlikely to be involved in covalent linkage to lysine
residues of target proteins, since it lacks the obligate
COOH-terminal glycine residue required for cleavage and
conjugation. Another possibility could be that the UB do-
main is modified by conjugation by either ubiquitin or other
small ubiquitin-like proteins (e.g., SUMO, NEDD8, etc.) to
its lysine group (or groups) forming ubiquitin-conjugates
(Pickart, 1998). This is also unlikely to occur, as ubiquilin
immunoblots did not show the expected ladder of ubiquitin-
conjugated bands. Therefore, the UB domain may play aMah et al. Ubiquilin Modulates Presenilin Protein Accumulation 861
role in some other function. For example, in yeast RAD23
and its human homologues (HHR23A and HHR23B), the
UB domains are involved in binding subunits of the protea-
some, whereas in XDRP1, the UB domain is necessary for
binding cyclin A. Clearly, insight into ubiquilin’s function
will emerge from an understanding of protein–protein inter-
actions and the roles of its different domains.
Using a combination of immunological and GFP-tag-
ging approaches, we have demonstrated that ubiquilin is
localized to both the nucleus and the cytoplasm in HeLa
cells. The intensity of nuclear staining was variable, with
some nuclei staining very brightly. The variability may be
related to cell cycle changes of cyclin A (a protein to which
ubiquilin’s homologue XDRP1 has been shown to inter-
act) levels within the nucleus. The cytoplasmic distribution
of ubiquilin was also variable. In untransfected cells, en-
dogenous ubiquilin had a fine punctate appearance, with
hints of association to a network-like pattern, possibly the
ER. In some of these cells, ubiquilin accumulated in larger
spherical structures throughout the cytoplasm, whose
number and size were variable. Upon ubiquilin overex-
pression, the cells formed even larger and more numerous
ubiquilin-containing structures. Under confocal micros-
copy, the ubiquilin staining pattern colocalized almost per-
fectly with the presenilin staining pattern. Considering
that the two presenilin interaction sites (COOH terminus
and loop domains) both face the cytoplasm according to
the predicted topology of presenilins in membranes, it is
not surprising that ubiquilin colocalized with ER mem-
brane-bound presenilin. Still, many other proteins have
also been shown to interact with these two domains of pre-
senilins. Clearly, understanding the dynamics of the differ-
ent protein–protein interactions should provide clues re-
garding presenilin functions. A study of mouse PLIC-1
and PLIC-2 suggested an involvement in linking integrins
via integrin-associated proteins to the vimentin cytoskele-
ton (Wu et al., 1999). We have not observed any signifi-
cant staining of ubiquilin to the cell periphery and do not
know if this is in any way related to the lack of expression
of particular integrin-associated proteins or integrins in
HeLa cells. Nevertheless, it is interesting that vimentin
and presenilins have been linked to one another in aggre-
somes, structures involved in the cellular response to mis-
folded proteins (Johnston et al., 1998). Moreover, recent
evidence indicates that aggresomes are involved in the re-
cruitment of the proteasome Hsp70 and chaperones (Gar-
cia-Mata et al., 1999), which circumstantially suggests a
mechanism by which ubiquilin could be associated with
proteins of the misfolded protein response.
There are the several lines of evidence that link ubiq-
uitin to genes and tissues involved in AD. First, presenilin
proteins are thought to be ubiquitinated, since treatment
with proteasome inhibitors cause the accumulation of
large complexes, which migrate in SDS gels in a manner
consistent with modification by ubiquitin (Kim et al., 1997;
Fraser et al., 1998; Honda et al., 1999). Second, it is well
known that ubiquitin immunoreactivity is strongly associ-
ated with the NFTs and senile plaques of AD, hallmark le-
sions of AD pathology (Mori et al., 1987; Perry et al.,
1987). The strong ubiquilin immunoreactivity associated
with NFTs and Lewy bodies is intriguing, considering that
these lesions are known to contain misfolded proteins. At
present, our results do not provide clues as to whether
ubiquilin is acting in a causative role or as an end result of
association with misfolded and accumulated proteins. We
plan to pursue this in the future.
In summary, ubiquilin is the first presenilin-interacting
protein, to our knowledge, that has been found to regulate
presenilin levels in cells. The presence of multiple ubiq-
uitin-related domains suggests ubiquilin may be involved
in the regulation of presenilin protein levels by the protea-
some-folding and/or degradation pathway.
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